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Abstract
Objective The purpose of this study was to evaluate the
effect of Cox-2 administration on direct (primary) fracture
healing.
Methods A transverse tibial osteotomy was created in
adult male rabbits and rigidly ﬁxed in compression using a
2.7-mm dynamic compression plate. Animals were randomized to receive either rofecoxib (12.5 mg orally per
day) or placebo. Animals were killed at 4 weeks and
fracture healing assessed by mechanical testing.
Results There were no signiﬁcant differences between
the control and Cox-2 treated animals in terms of
mechanical strength at 4 weeks. There was a high com
plication rate of peri-implant fractures during the daily
medication administration.
Conclusion The immediate administration of a Cox-2
speciﬁc inhibitor did not impair primary (direct) bone
healing at the dose administered in this rabbit tibial oste
otomy model.

Introduction
Fracture healing has classically been divided into either
primary (direct) or secondary fracture healing. Primary
fracture healing occurs when the cortex is anatomically
reduced and rigidly ﬁxed with a compression plate. The
process involves osteoclasts in cutting cones crossing
the fracture site and forming new osteons that bridge the
fracture gap. In comparison, secondary bone healing occurs
when there is relative motion between the fracture frag
ments and a large external callus is formed with subsequent
endochondral and intramembranous bone formation.
The majority of preclinical studies have shown that non
speciﬁc non-steroidal anti-inﬂammatory drugs (NSAIDs)
impair secondary bone healing [1–4]. Several studies have
also shown that a speciﬁc class of NSAIDs, cyclooxygen
ase-2 (Cox-2) speciﬁc inhibitors, delays healing and
decreases fracture strength in animal models that heal by
secondary bone healing [5–8]. These studies have exam
ined the effect of Cox-2 inhibitors in a standard rat femoral
fracture model in which the femur was loosely stabilized
with a non-locked intramedullary k-wire. This method of
ﬁxation permits residual motion at the fracture site, and the
fracture heals through the production of callus and sec
ondary (indirect) bone healing. Other studies have shown
that the administration of both nonspeciﬁc and speciﬁc
Cox-2 inhibitors decreased the number of osteoclast-like
cells in a bone ingrowth model [9]. Since osteoclasts play a
critical role in primary bone healing, their impairment by
Cox-2 inhibitors may conceivably lead to impaired primary
(direct) bone healing.
Prior to the widespread publicity about increased cardiac
complications associated with the use of certain Cox-2
inhibitors, Cox-2 inhibitors had become widely prescribed
for common orthopedic conditions, and their use had been

advocated as part of a multi-modality approach for postop
erative pain control [10–15]. Following fracture ﬁxation
there is said to be a race between fracture healing and failure
of ﬁxation. If Cox-2 speciﬁc inhibitors impair primary
(direct) bone healing, their use following rigid internal ﬁx
ation of fractures might lead to ﬁxation failure and nonunion.
The purpose of this study was to investigate whether Cox-2
inhibitors impair primary (direct) bone healing in fractures
that are anatomically reduced and rigidly ﬁxed.

Methods
Animal model
One-year-old skeletally mature male New Zealand White
rabbits were used under a protocol approved by our Institu
tional Animal Use and Care Committee. Animals ranged in
weight from 3.0 to 3.5 kg with similar mean weights between
the two groups. Anesthesia was initiated with a SQ injection
of ketamine (50 mg/kg), xylazine (5 mg/kg) and AcePro
mazine (0.5 mg/kg), and maintained with alternating IV
injections of ketamine (20 mg) and xylazine (2 mg) as nee
ded. An intravenous catheter was inserted into the dorsal ear
vein and 0.9% sodium chloride or LRS infused throughout
the procedure (10 mg/kg/min). The antibiotic Baytril
(10 mg/kg) was administered IM preoperatively. Postopera
tively the animals received Buprenorphine IM (0.01 mg/kg)
and Baytril IM (10 mg/kg) every 12 h for 3 days.
The animals right hindlimb was prepped with betadine
and sterilely draped. A longitudinal incision was made over
the anterior tibial crest. A saline-cooled oscillating saw was
used to produce a transverse mid-diaphyseal tibial osteot
omy to simulate a fracture [16]. The osteotomy was ana
tomically reduced and internally ﬁxed in compression with
a six-hole, 2.7-mm dynamic compression plate (Synthes,
Paoli, PA) and six bicortical screws. AP and lateral
radiographs were obtained immediately postoperatively to
document the reduction and ﬁxation accuracy.
Animals were randomized to receive either placebo
(sugar pill) or rofecoxib (Merck and Co., Inc., Whitehouse
Station, NJ) 12.5 mg/day administered orally once daily
for 4 weeks and then discontinued. The tablet was covered
in a tasty jelly and inserted directly into the rabbit’s mouth
by a veterinary technician.
The animals were housed individually in standard cages
and provided fresh water and chow ad libitum. Animals
were maintained for 28 days and then euthanized. Two
additional animals that received placebo for the ﬁrst
28 days were maintained for a total of 8 weeks in order to
examine the osteotomy healing rate. Animals in which
there was evidence of ﬁxation loss or infection were
excluded from the study and humanely euthanized.

Mechanical testing
After sacriﬁce, both tibia were harvested and cleaned of soft
tissues. The plate was removed and the ends of the bone
potted in methacrylate. The specimens were secured in a
custom ﬁxture for torsion testing and mounted in an Instron
8511 Universal Testing Machine (Instron Corp., Norwood,
MA). Specimens were tested in torsion at a rate of 10� per
minute until failure. Rotational displacement and torque data
were collected at 100 Hz. Maximum torque was measured
directly from the data, and torsional stiffness was calculated
from a regression of the linear portion of the torque versus
angular displacement curve. The energy absorption to failure
was also calculated as the area under the curve to the maxi
mum value. The nonfractured contralateral intact femur was
also tested to calculate normalized values of maximum tor
que (percent maximum torque), stiffness (percent stiffness)
and energy absorption to failure (percent energy) in order to
reduce the inﬂuence of individual animal differences.
The location of the failure with respect to the osteotomy
site was recorded. Specimens that failed directly through
the osteotomy site were classiﬁed as nonunions. Specimens
that failed with a spiral fracture that crosses the fracture
site were classiﬁed as a union. Specimens that show some
evidence of bone bridging at the osteotomy site but that
failed primarily through the osteotomy were be classiﬁed
as an incomplete union [17].
Histology
Following mechanical testing the specimens were removed
from their potting ﬁxture, and the two fragments of the
fracture reapproximated and held with narrow gauge wire.
The specimens were ﬁxed in 4% paraformaldehyde with
0.1 M phosphate buffer for 24 h. They were then defatted
in 70% ethanol and decalciﬁed with 10% formic acid in
citrate. The specimens were sliced in half longitudinally
and embedded in parafﬁn. Parafﬁn sections (4 lm thick)
were cut and stained with hematoxylin and eosin.
Statistical analysis
A pre hoc power analysis was performed based on an
average control maximum torque to failure of 1.8 N m
with a standard deviation of 0.2. Assuming a 20% differ
ence, ﬁve animals per group were required to provide a
80% power with an alpha level of 0.5. The means and
standard deviations of the mechanical test data of osteo
tomized and intact tibia were calculated. The 95% conﬁ
dence interval for the mean was calculated for each group.
An unpaired T test with unequal variance was used to
compare the mechanical results of the rofecoxib-treated
animals with the placebo-treated animals.

Table 1 Mechanical test results of 4-week animals (mean and standard deviation)
Treatment

Side

Maximum torque
to failure (N m)

Stiffness (N m/deg)

Energy absorption to
maximum torque (N m deg)

Placebo (n = 5)

Osteotomy

1.448 ? 0.386

0.127 ± 0.059

14.278 ± 4.453

Intact

2.845 ± 0.383

0.153 ± 0.026

24.882 ± 6.033

Rofecoxib (n = 7)

Osteotomy

1.581 ± 0.302

0.117 ± 0.057

16.396 ? 2.786

Intact

3.218 ± 0.535

0.163 ± 0.022

30.269 ? 7.256

Results
There was a high rate of peri-implant fracture during ani
mal handling for administration of the study medication in
the immediate postoperative period. Sixteen animals sus
tained some peri-implant fracture or loss of ﬁxation, and
were euthanized prior to study completion. Fifteen of these
failures occurred during the ﬁrst 6 postoperative days,
while one occurred at day 25. Loss of ﬁxation and healing
with angulation and callus occurred in four other animals
(three placebo, one rofecoxib). This was discovered on
radiographs and examination at the time of sacriﬁce, and
these specimens were excluded from the study. Twelve
animals, maintained for 4 weeks, whose radiographs
showed stable ﬁxation and no loss of alignment were used
for mechanical analysis. Seven of these animals received
rofecoxib, and ﬁve received placebo.
All specimens failed with production of a spiral fracture.
None of the specimens failed solely through the osteotomy
site. In the 4-week animals, seven specimens failed par
tially through the osteotomy site (3 placebo, 4 rofecoxib)
and were categorized as incomplete unions. Five specimens
(2 placebo, 3 rofecoxib) failed outside of the osteotomy
site, usually though a distal screw hole, and were catego
rized as unions. In the 8-week animals, one failed partially
through the osteotomy site (incomplete union), and one
failed outside the osteotomy site (union).
At 4 weeks, the difference in the osteotomy site maxi
mum torque to failure (Table 1) between the placebo- and
the rofecoxib-treated animals was not signiﬁcant (p =
0.54). The 95% conﬁdence interval of the osteotomy site
maximum torque of the placebo group was 0.34–1.79 N m
and of the rofecoxib group was 0.22–1.80 N m. When
normalized to the intact side, the % maximum torque to
failure of the osteotomy site was approximately 50% of the
intact side for both the placebo and rofecoxib groups
(Fig. 1).
There was also no signiﬁcant difference between
the placebo- and rofecoxib-treated groups for stiffness
(p = 0.77) or for the energy absorption to maximum torque
(p = 0.38). The 95% conﬁdence interval of the osteotomy
site stiffness of the placebo group was 0.05–0.18 N m/deg
and of the rofecoxib group was 0.04–0.16 N m/deg. The

Fig. 1 Normalized values and standard deviations of mechanical test
data: maximum torque, stiffness and energy absorption to maximum
torque

95% conﬁdence interval of the osteotomy site energy
absorption to maximum torque for the placebo group was
3.90–18.18 N m deg and for the rofecoxib group was
2.06–18.46 N m deg. Normalized values for the stiffness
came closer to approximating the intact side for both the
placebo group and the rofecoxib group; however, the
standard deviation was large.
The maximum torque to failure of the two animals
treated with placebo and maintained for a total of 8 weeks
was 1.50 and 1.68 N m, which was not signiﬁcantly dif
ferent from that seen in the placebo group at 4 weeks
(average maximum torque 1.45 N m).
Intramembranous bone formation, aligned perpendicular
to the longitudinal axis, was found to be present in the
narrow gap present between the ends of the osteotomy sites
(Fig. 2). Evidence of osteoclastic cutting cones with for
mation of new osteons was seen traversing the healed
osteotomy sites (Fig. 3). Many of the specimens also
showed some periosteal bone formation adjacent to the
osteotomy site.

Discussion
In this rabbit tibial osteotomy model, we did not ﬁnd any
signiﬁcant difference in the mechanical strength of direct
fracture healing in animals treated with rofecoxib (12.5 mg
daily dose) compared with placebo. However, we must
caution that due to the small sample size we may not have
been able to identify an actual difference between the

Fig. 2 Intramembranous bone formation is seen ﬁlling the narrow
gap present between the ends of the osteotomy sites in a placebotreated animal. Note that the bone is aligned perpendicular to the
longitudinal axis. H&E, 920

Fig. 3 New osteonal bone formation seen traversing the osteotomy
site in a rofecoxib-treated animal. H&E, 940

groups that may exist. The model selected for this study
resulted in an unacceptably high complication rate, with a
peri-implant fracture occurring in 16 animals and loss of
ﬁxation leading to fracture angulation in an additional 4
animals. The high complication rate with this animal model
leads us to discourage its use for other studies examining
primary (direct) bone healing.
Absolute stability with interfragmentary compression is
necessary to achieve primary (direct) bone healing. We
attempted to achieve interfragmentary compression of the
transverse osteotomy site by eccentric screw placement in
the holes of the 2.7 mm dynamic compression plates. The
presence of a small gap between the ends of the osteotomy
site in most sections suggests that only limited interfrag
mentary compression was achieved. In addition, the pres
ence of periosteal bone formation suggests that there may

have been some residual motion present at the osteotomy
site. Alternatively this bone formation could be reactive
due to inadvertent elevation of the periosteum around the
osteotomy site. The presence of new osteonal bone for
mation traversing the osteotomy site does suggest that the
model does involve primary (direct) bone healing. Because
many of the healed specimens contained a combination of
primary (direct) bone healing and periosteal bone forma
tion adjacent to the osteotomy site, our mechanical test data
do not reﬂect the contribution of primary (direct) bone
healing alone.
As with any study there were problems and weaknesses
associated with our investigation. The rofecoxib dosage
selected was based on that used in prior studies; however,
this may not be the appropriate effective dose due to dif
ferences in absorption and metabolism in this species [9].
We chose to give the medication directly into the rabbit’s
mouth, rather than in their feed, to ensure consistent
administration. Many fractures occurred because of the
rabbits’ forced hindlimb movements during medication
administration. Even in animals in which catastrophic
failure did not occur, loss of ﬁxation still occurred, leading
to further exclusion of animals. Because of the difﬁculties
using this model we did not have separate specimens
available for a more thorough quantitative histologic
evaluation.
We examined only a single 4-week timepoint and may
have missed subtle differences that rofecoxib may have had
on the rate of fracture healing. We chose to examine the
mechanical strength of healing at 4 weeks; however, other
investigators have shown that the strength of plated rabbit
tibia increased up to 6 weeks when tested in bending mode
[18]. Because the process of primary bone healing is more
gradual than secondary bone healing, the 4-week timepoint
may have been too early since some other investigators
have reported that osteonal bridging occurred at 6 weeks or
later [16]. Difﬁculties with the animal model led us to
abandon plans to study a larger group of animals at an
8-week timepoint.
There is conﬂicting information about the effect of Cox
2 inhibition on fracture healing. Several pre-clinical studies
have reported that Cox-2 inhibitors result in impaired
fracture healing in animal models that heal by secondary
(indirect) bone healing [5–8]. The magnitude of the detri
mental effect of selective Cox-2 inhibitors on secondary
fracture healing has been shown to be related to the dura
tion of treatment [6]. Celecoxib administered during the
ﬁrst 2 weeks after fracture signiﬁcantly impaired fracture
healing in a rat secondary fracture healing model, whereas
treatment prior to fracture or initiated 14 days after fracture
did not impair secondary fracture healing [7].
Other studies, however, have reported that some Cox-2
inhibitors have a less detrimental effects on fracture

healing than non-speciﬁc nonsteroidal anti-inﬂammatories
[19–22]. Brown and colleagues [19] found no decrease in
the mechanical strength of rat femur fracture healing at 4, 8
and 12 weeks in animals treated with celecoxib (3 mg/kg).
While they did report that the celecoxib treated fractures
appeared to have more ﬁbrous tissue than controls at 4 and
8 weeks, they found no signiﬁcant difference in the degree
of radiographic callus and the mechanical strength. Simon
and colleagues reported that rofecoxib (4 mg/kg) signiﬁ
cantly diminished the mechanical properties of a standard
rat femur fracture at 8 weeks, but that celecoxib (3 mg/kg)
showed no signiﬁcant difference in the mechanical prop
erties of the fracture when compared to controls [20].
Karachalios et al. compared the effect of short-term
administration of rofecoxib with non-selective NSAIDs
and prednisolone on secondary fracture healing in a rabbit
ulna osteotomy model. They administered rofecoxib
(0.5 mg/kg/24 h) orally for 5 consecutive days. While all
the biomechanical parameters of prednisolone, indomethi
cin and meloxicam were signiﬁcantly lower than in the
control group, only the fracture load values of rofecoxib
were lower than the control. The histomorphometric
parameters showed the least negative effects in the rofec
oxib group. The investigators concluded that the short-term
administration of rofecoxib had only a minor negative
effect on bone healing [21].
Gerstenfeld and colleagues [23] characterized the
expression of Cox-1 and Cox-2 mRNA in rat fracture
calluses at timed intervals after fracture using real-time
PCR. They found that Cox-2 mRNA levels showed peak
expression during the ﬁrst 14 days of healing and returned
to baseline levels by day 21. In addition they examined the
effect of ketorolac (4 mg/kg), a non-speciﬁc NSAID, and
two doses of parecoxib (0.3 and 1.5 mg/kg), a pro-drug of
valdecoxib, in a rat femur fracture model. They found
signiﬁcant reduction in the mechanical properties of ani
mals treated with ketorolac at 21 days post-fracture. While
the mean mechanical strength of the parecoxib-treated
animals was less at 21 days, it was not statistically sig
niﬁcant. They concluded that a Cox-2-selective NSAID
such as parecoxib has only a small effect on delaying
fracture healing, even at doses that are known to fully
inhibit prostaglandin production.
Utilizing a knockout mouse model, Zhang and col
leagues [24] demonstrated that Cox-2 plays an essential
role in both endochondral and intramembranous bone for
mation during skeletal repair. The healing of stabilized
tibia fractures was signiﬁcantly delayed in the Cox-2-/
mice compared to the Cox-1-/- and the control wild-type
mouse. The histology of the ﬁbrous nonunions in the Cox2-/- mice was characterized by a persistence of undif
ferentiated mesenchyme and a marked reduction in
osteogenesis.

While some authors have expressed caution in the use of
Cox-2 inhibitors in patients following fracture or other
surgery requiring bone healing, others have questioned the
clinical importance of the published animal data [25].
Similar concerns have been raised about the larger body of
literature that has examined the effect of non-Cox-2 spe
ciﬁc nonsteroidal anti-inﬂammatories on fracture healing in
animal models. However, two clinical reports have raised
concern about the effect of NSAIDs on fracture healing. In
one study, patients who received indomethicin as prophy
laxis for heterotopic ossiﬁcation following surgical treat
ment of acetabular and long bone fractures had a
signiﬁcantly greater rate of long bone nonunion (26 vs. 7%,
p = 0.004) [26]. In a second retrospective study investi
gators found a statistically signiﬁcant (p = 0.000001)
association between nonunion of the femoral diaphysis and
use of NSAIDs after injury [27].
While there may be other reasons to avoid the use of
Cox-2 inhibitors in certain patients, the necessity for pri
mary (direct) bone healing need not be a contraindication
for their use. The immediate administration of a Cox-2
speciﬁc inhibitor did not impair primary (direct) bone
healing at the dose administered in this rabbit tibial oste
otomy model.
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